- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07243743
Assessment of the Glycemic Responses to Nutritional Products-INQ-2526 (GLIN#5)
April 30, 2026 updated by: Nutricia Research
Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals
This study assesses the glycemic responses to nutritional products.
During a study visit fasted subjects will consume a serving of the reference product or the test product.
Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period.
Several nutritional products will be tested over time.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5C 2N8
- INQUIS Clinical Research, Ltd , 20 Victoria Street, 3rd Floor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age ≥ 18 and ≤ 65 years
- Body mass index (BMI) between 18.5 and 27 kg/m²
Exclusion Criteria:
- Fasting Glucose ≥6.1 at screening visit
- Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results.
- Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
- Major trauma or surgical event within 3 months of screening.
- Known intolerance, sensitivity or allergy to test products.
- Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
- History of cancer in the prior two years, except for non-melanoma skin cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Arm 1
All subjects will receive all interventions during the trial.
The order of the Nutritional products will be randomized.
|
dextrose (containing 10 grams of carbohydrates)
|
|
Other: Arm 2
All subjects will receive all interventions during the trial.
The order of the Nutritional products will be randomized.
|
dextrose (containing 10 grams of carbohydrates)
|
|
Other: Arm 3
All subjects will receive all interventions during the trial.
The order of the Nutritional products will be randomized.
|
dextrose (containing 10 grams of carbohydrates)
|
|
Other: Arm 4
All subjects will receive all interventions during the trial.
The order of the Nutritional products will be randomized.
|
high protein beverage no sugar 1
|
|
Other: Arm 5
All subjects will receive all interventions during the trial.
The order of the Nutritional products will be randomized.
|
high protein beverage no sugar 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The glycemic index of nutritional products
Time Frame: From enrollment to the end of treatment at about 6 weeks
|
From enrollment to the end of treatment at about 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
1. The postprandial glucose levels at each time point after each test product compared with the mean of the 3 references
Time Frame: From enrollment to the end of treatment at about 6 weeks
|
From enrollment to the end of treatment at about 6 weeks
|
|
2. The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 references
Time Frame: From enrollment to the end of treatment at about 6 weeks
|
From enrollment to the end of treatment at about 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 17, 2025
Primary Completion (Actual)
December 3, 2025
Study Completion (Actual)
December 3, 2025
Study Registration Dates
First Submitted
November 17, 2025
First Submitted That Met QC Criteria
November 17, 2025
First Posted (Actual)
November 24, 2025
Study Record Updates
Last Update Posted (Actual)
May 1, 2026
Last Update Submitted That Met QC Criteria
April 30, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- 25REX0091089 - GLIN#5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycemic Response
-
Mondelēz International, Inc.Reading Scientific Services Ltd.Completed
-
Glycemic Index Laboratories, IncUniversity of Guelph; Guelph Research and Development Centre, Agriculture and...Completed
-
Purdue UniversityPepsiCo Global R&DCompletedGlycemic Response
-
PepsiCo Global R&DGlycemic Index Laboratories, IncCompleted
-
Nutricia ResearchINQUIS Clinical ResearchCompletedGlycemic ResponseCanada
-
INQUIS Clinical ResearchUniversity of SaskatchewanCompleted
-
Nutricia ResearchCompletedGlycemic ResponseCanada
-
PepsiCo Global R&DCompletedGlycemic Response | Insulinemic Response | Subject Hunger ResponseCanada
Clinical Trials on First Reference Product
-
Nutricia ResearchRecruitingGlycemic ResponseCanada
-
Nutricia ResearchINQUIS Clinical ResearchCompletedGlycemic ResponseCanada
-
Nutricia ResearchCompletedGlycemic ResponseCanada
-
Nutricia ResearchCompletedPostprandial HypoglycemiaNetherlands
-
Örebro University, SwedenActive, not recruitingCognitive FunctionSweden
-
GlaxoSmithKlineCompletedSports Nutritional SciencesUnited Kingdom
-
Region SkaneLund University; Berry LabCompletedMemory Impairment | Cognitive Impairment, MildSweden
-
Padagis LLCCompleted
-
GlaxoSmithKlineCompletedDenture RetentionUnited States